title: The regulation of oestrone sulphate formation in breast cancer cells.
abstract: The formation of oestrone sulphate has been examined in MCF-7 (oestrogen receptor positive, ER+) and MDA-MB-231 (ER negative, ER-) breast cancer cells. Using intact cell monolayers and a physiological substrate concentration, progesterone (1 microM) and dexamethasone (1 microM) both increased oestrone sulphate formation in MCF-7 cells. In MDA-MB-231 cells, dexamethasone, but not progesterone, increased conjugate formation. A number of growth factors, cytokines and human serum albumin (HSA), which have previously been found to regulate oestrogen synthesis, were also examined for their ability to regulate oestrone sulphate formation. In MCF-7 cells epidermal growth factor, acidic and basic fibroblast growth factors, insulin-like growth factor-type I and insulin all stimulated oestrone sulphate formation. The cytokines, tumour necrosis factor alpha (TNFalpha) and interleukin-1beta also increased conjugate formation in the ER+ cells, as did HSA. In contrast, in MDA-MB-231 cells TNFalpha was without effect and HSA inhibited oestrone sulphate formation. The ability to modulate oestrone sulphate formation in ER+ cells may be an important mechanism to limit the availability of oestrogen to interact with the ER.
authors.affiliation: Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St. Mary's Hospital, London, UK.
authors.forename: A
authors.initials: A
authors.lastname: Purohit
authors.forename: C V
authors.initials: CV
authors.lastname: de Giovani
authors.forename: M J
authors.initials: MJ
authors.lastname: Reed
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism*; D016207:Cytokines / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004970:Estrone / Q000031:analogs & derivatives* / Q000378:metabolism; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D007700:Kinetics; D011960:Receptors, Estrogen; D012709:Serum Albumin; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D016207:Cytokines; D006133:Growth Substances; D007328:Insulin; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D011960:Receptors, Estrogen; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D004970:Estrone; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; C017296:estrone sulfate